Möchten Sie immer auf dem neuesten Stand bleiben?

호주 아들레이드, July 10, 2026 (GLOBE NEWSWIRE) -- 호주에 본사를 둔 글로벌 임상시험수탁기관(CRO)인 아반스 클리니컬(Avance Clinical)은 7월 15일부터 19일까지 대만 타이베이 난강전시센터(Taipei Nangang Exhibition Center, TaiNEX)에서 열리는 'BIO Asia–Taiwan...

Avance Clinical to Showcase Asia and China Growth Strategy at BIO Asia–Taiwan 2026

Avance Clinical to Showcase Asia and China Growth Strategy at BIO Asia–Taiwan 2026

First gene replacement therapy in the EU for broad population with SMA, including children two years and older, teens and adults Fixed, one-time dose designed to replace the faulty SMN1 gene,...

SK pharmteco announces a collaborative agreement with the Orphan Therapeutics Accelerator (OTXL) to support the advancement of novel therapeutic programs.

Phase III ALIGN study results showed reduced rate of kidney function decline by ~34% with Vanrafia vs placebo, based on supportive eGFR slope analysis1Vanrafia reduced protein in urine by 38.3% vs...

Late-breaking Phase III IgAN data for Vanrafia ALIGN and Fabhalta APPLAUSE-IgAN studies to be presented124-week Phase I/II zigakibart data evaluating treatment efficacy and safety in IgAN will be...

ODDIFACT obtient la désignation médicament orphelin de l'EMA pour l'infliximab dans la maladie de Kawasaki, après la FDA. Essai KIDCARE dans The Lancet.

ODDIFACT obtient la désignation médicament orphelin de l'EMA pour l'infliximab dans la maladie de Kawasaki, après la FDA. Essai KIDCARE dans The Lancet.

- Continued advancement of the ongoing Phase 1 study of RT-114 via RaniPill® for the treatment of obesity in collaboration with ProGen – - Appointed Alireza Javadi, Ph.D. as Chief Technical Officer -...